Assessment of treatment-associated changes in behavior and cholinergic therapy of neuropsychiatric symptoms in Alzheimer's disease.
Alzheimer's disease affects multiple domains of human brain function and has neuropsychological, neuropsychiatric, and neurologic manifestations. Behavioral changes should be assessed as part of a comprehensive evaluation of the effects of cholinergic treatment of Alzheimer's disease. The psychometric properties, origin, source of behavioral information, content, and administration requirements of tools used to assess behavior in Alzheimer's disease affect the type of information garnered and the conclusions that can be derived. Assessment of drug-related behavioral changes can be affected by spontaneous remission of neuropsychiatric symptoms, differing baseline severity of behavioral abnormalities, uncertain magnitude of expected treatment effects, and by the influence of disease stages, concurrent medications, and comorbid conditions. Cholinergic therapies ameliorate behavioral alteration in Alzheimer's disease, and changes in behavior should be monitored when such therapy is initiated.
Department of Neurology, University of California at Los Angeles, School of Medicine, West Los Angeles Veterans Affairs Medical Center, 90095-1769, USA.
J L
JL
Cummings
D L
DL
Masterman
D000368:Aged; D000544:Alzheimer Disease / Q000175:diagnosis* / Q000188:drug therapy* / Q000523:psychology; D000818:Animals; D014150:Antipsychotic Agents / Q000627:therapeutic use; D018678:Cholinergic Agents / Q000627:therapeutic use*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D015897:Comorbidity; D006801:Humans; D001523:Mental Disorders / Q000175:diagnosis* / Q000188:drug therapy* / Q000523:psychology; D009483:Neuropsychological Tests / Q000706:statistics & numerical data; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D011594:Psychometrics; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D015203:Reproducibility of Results
D014150:Antipsychotic Agents; D018678:Cholinergic Agents; D002800:Cholinesterase Inhibitors; D011619:Psychotropic Drugs